How is Hantavirus pulmonary syndrome treated?

Hantavirus pulmonary syndrome (HPS) is a severe respiratory disease caused by infection with hantaviruses. Treatment options for HPS are critical due to its high mortality rate.

Key insights from the research papers include:

Extracorporeal membrane oxygenation (ECMO) has been used as a rescue therapy for adult patients with severe cardiopulmonary failure due to HPS, with some patients surviving after receiving ECMO support.
Early recognition of HPS and transport to intensive care, along with limited fluid replacement, early inotropic therapy, and mechanical ventilation, have been shown to improve survival rates.
Mechanical ventilation and corticosteroid pulse therapy have been used in the treatment of HPS, resulting in successful outcomes in some cases.
Targeted therapeutic approaches focusing on the vascular and lymphatic endothelial cells, which are central to the function of pulmonary capillary beds, may offer potential treatments to reduce the severity of HPS.
The addition of an arterio-venous shunt to conventional veno-arterial extracorporeal life support (ECLS) techniques has been reported as a successful management strategy for a patient with HPS.

In conclusion, the treatment of Hantavirus pulmonary syndrome involves a combination of supportive care and advanced medical interventions. ECMO has been highlighted as a beneficial therapy for severe cases, while early intensive care and mechanical ventilation are important for improving survival rates. Additionally, targeted therapies aimed at endothelial cells and the use of arterio-venous shunts in ECLS may represent promising strategies for managing this life-threatening condition.

How is Hantavirus pulmonary syndrome treated?

Summary

Sources and full results

Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation.

ECMO is a beneficial therapy for critically ill patients with severe Hantavirus pulmonary syndrome, providing cardiopulmonary support and a good outcome in two cases.

Hantavirus Cardiopulmonary Syndrome

Early recognition and intensive care improve survival in hantavirus cardiopulmonary syndrome patients, with hyperimmune serum showing promise as a promising future therapy.

A Case of Hantavirus Pulmonary Syndrome

Hantavirus pulmonary syndrome (HPS) is a rapidly progressive, noncardiogenic edema-causing virus with a high mortality rate, and can be successfully treated with mechanical ventilation and initial corticosteroid pulse therapy.

Role of vascular and lymphatic endothelial cells in hantavirus pulmonary syndrome suggests targeted therapeutic approaches.

Hantaviruses cause acute pulmonary edema by altering vascular barrier functions of microvascular and lymphatic endothelial cells, suggesting targeted therapeutic approaches could reduce the severity of HPS disease.

[Addition of an arterio-venous shunt during veno-arterial extracorporeal life support in a patient with Hantavirus pulmonary syndrome].

An arterio-venous shunt added to veno-arterial extracorporeal life support successfully managed a patient with Hantavirus pulmonary syndrome, reducing mortality and improving survival rates.

Hantavirus Pulmonary Syndrome: Pathogenesis of an Emerging Infectious Disease

Hantavirus pulmonary syndrome (HPS) is a newly recognized, often fatal disease caused by a previously unrecognized hantavirus, and may be an important cause of severe and fatal adult respiratory distress syndrome.

Hantavirus Pulmonary Syndrome

Hantavirus pulmonary syndrome is a sporadic and uncommon infectious syndrome with a high mortality rate, requiring early recognition and prevention in rural settings.

Fatal hantavirus pulmonary syndrome in an adolescent.

Hantavirus pulmonary syndrome (HPS) is a fatal viral zoonosis caused by three newly identified hantaviruses, with a febrile prodrome and severe noncardiogenic pulmonary edema.

Hantavirus pulmonary syndrome in the United States

Hantavirus pulmonary syndrome (HPS) is a widespread and potentially fatal disease, with new research identifying cellular receptors and the immune system's role in pathogenesis.

Acute Sin Nombre hantavirus infection without pulmonary syndrome, United States.

Five cases of acute Sin Nombre hantavirus infection occurred in the United States without severe pulmonary involvement, suggesting that expanded surveillance for hantavirus pulmonary syndrome may be needed.

Try another search